# Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.

> **NCT00295594** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 627 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** tacrolimus

## Key facts

- **NCT ID:** NCT00295594
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 627 (ACTUAL)
- **Last updated:** 2014-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295594, "Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00295594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*